“Conservative revenue forecasts call for $2.1 -
Post# of 148181
IMO, $2.1-$4.2 billion in the first year is not conservative, but a little high. I’m assuming that’s an estimate for combo therapy, but maybe they included mTNBC as well. I just think market penetration for combo will take some time, mainly to get Leronlimabs’s name out there. Won’t take as long for cancer.